Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

被引：0

作者：

Serrano, C. ^{[1
]}

Blay, J-Y. ^{[2
]}

Rutkowski, P. ^{[3
]}

Gelderblom, H. ^{[4
]}

Stacchiotti, S. ^{[5
]}

Falcon Gonzalez, A. ^{[6
,7
]}

Desai, J. ^{[8
]}

Le Cesne, A. ^{[9
]}

Ferraresi, V. ^{[10
]}

Palmerini, E. ^{[11
]}

Wilky, B. A. ^{[12
]}

Wagner, A. J. ^{[13
]}

Bernthal, N. M. ^{[14
]}

van de Sande, M. ^{[15
]}

Narasimhan, S. ^{[16
]}

Harrow, B. ^{[16
]}

Sharma, M. G. ^{[16
]}

Ruiz-Soto, R. ^{[16
]}

Sherman, M. L. ^{[16
]}

Tap, W. D. ^{[17
]}

机构：

[1] Vall dHebron Inst Oncol, Sarcoma Translat Res, Barcelona, Spain

[2] Ctr Leon Berard, Med, Lyon, France

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[4] Leiden Univ Med Ctr, Med Oncol, Leiden, Netherlands

[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[6] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain

[7] Inst BioMed Sevilla, Seville, Spain

[8] Peter MacCallum Canc Ctr, Clin Res, Melbourne, Vic, Australia

[9] Gustave Roussy, Inst Cancerol, Villejuif, France

[10] IRCCS Ist Nazl Tumori Regina Elena, Sarcomas & Rare Tumors Dept Unit, Rome, Italy

[11] Ist Ortoped Rizzoli, DIMES Expt Diagnost & Specialty Med, Bologna, Italy

[12] Univ Colorado, Ctr Canc, Med Oncol, Aurora, CO USA

[13] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[14] Univ Calif Los Angeles, Orthopaed Surg, Los Angeles, CA USA

[15] Leiden Univ Med Ctr, Orthoped Oncol, Leiden, Netherlands

[16] Deciphera Pharmaceut LLC, Clin Dev, Waltham, MA USA

[17] Mem Sloan Kettering Canc Ctr, Sarcoma Med Oncol, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1860

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1769P

引用

页码：S1053 / S1053

页数：1

共 50 条

[1] Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
D'Amato, G.
Wagner, A. J.
Ganjoo, K. N.
Stacchiotti, S.
Gelderblom, H.
Ryan, C. W.
Palmerini, E.
Ravi, V.
Saleh, R.
Le Cesne, A.
Bernthal, N. M.
van de Sande, M.
Narasimhan, S.
Harrow, B.
Saunders, A.
Ruiz-Soto, R.
Sherman, M. L.
Tap, W. D.
ANNALS OF ONCOLOGY, 2024, 35 : S1054 - S1054
[2] Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
Gelderblom, H.
Bhadri, V. A.
Stacchiotti, S.
Bauer, S.
Wagner, A. J.
van de Sande, M.
Bernthal, N. M.
Pousa, A. Lopez
Razak, A. R. Abdul
Italiano, A.
Ahmed, M.
Le Cesne, A.
Tait, C.
Saunders, A.
Harrow, B.
Sharma, M. G.
Ruiz-Soto, R.
Sherman, M. L.
Blay, J-Y.
Tap, W. D.
ANNALS OF ONCOLOGY, 2024, 35 : 1265 - 1265
[3] CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Gelderblom, Hans
Razak, Albiruni A.
Taylor, Matthew H.
Bauer, Todd M.
Wilky, Breelyn
Martin-Broto, Javier
Gonzalez, Alejandro F.
Rutkowski, Piotr
Szostakowski, Bartlomiej
Alcindor, Thierry
Saleh, Ramy
Genta, Sofia
Stacchiotti, Silvia
van de Sande, Michiel
Wagner, Andrew J.
Bernthal, Nicholas
Davis, Lara E.
Vuky, Jacqueline
Tait, Christopher
Matin, Bahar
Narasimhan, Supraja
Sharma, Maitreyi G.
Ruiz-Soto, Rodrigo
Sherman, Matthew L.
Tap, William D.
CLINICAL CANCER RESEARCH, 2024, 30 (18) : 3996 - 4004
[4] A novel colony-stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor
Lipplaa, Astrid
Meijer, Debora
van de Sande, Michiel A. J.
Gelderblom, Hans
Bovee, Judith V. M. G.
Mei, Hailiang
Szuhai, Karoly
GENES CHROMOSOMES & CANCER, 2023, 62 (04): : 223 - 230
[5] Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update
Xu, Hairong
Zhou, Yong
Li, Binghao
Xie, Xianbiao
Du, Xinhui
Yuan, Ting
Chen, Bo
Zou, Qingping
Guo, Qiuxiang
Liang, Pan
Wang, Chen
Shan, Boyao
Tong, Zhichao
Dong, Yang
Yao Weitao
Shen, Jingnan
Ye, Zhaoming
Tu, Chongqi
Niu, Xiaohui
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.
Gelderblom, Hans
Tap, William D.
Palmerini, Emanuela
Stacchiotti, Silvia
Wainberg, Zev A.
Desai, Jayesh
Healey, John H.
van de Sande, Michiel
Bernthal, Nicholas M.
Peterfy, Charles
Shuster, Dale Edward
Wang, Qiang
Hsu, Henry
Wagner, Andrew J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor
Gelderblom, H.
Huang, M.
van de Sande, M.
Scharschmidt, T.
Kostogryz, O.
Alani, L.
Huang, T.
Hsu, L.
Johnson, K.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1226 - S1226
[8] A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antbody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).
Sankhala, Kamalesh Kumar
Blay, Jean-Yves
Ganjoo, Kristen N.
Italiano, Antoine
Hassan, Andrew Bassim
Kim, Tae Min
Ravi, Vinod
Cassier, Philippe Alexandre
Rutkowski, Piotr
Sankar, Neil
Qazi, Ibrahim
Sikorski, Robert S.
Collins, Helen
Zhang, Charlie
Shocron, Ellyn
Gelderblom, Hans
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse type tenosynovial giant cell tumor
Taylor, Matthew H.
Leong, Stephen
Su, Ying
Leary, Cynthia B.
Li, Xiaoyan
Kuida, Keisuke
Ruiz-Soto, Rodrigo
Bauer, Todd
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[10] A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial).
Cortes-Franco, Jorge
Coutre, Steven
Di Bona, Eros
Lo-Coco, Francesco
Wetzler, Meir
Sanz, Miguel
Wieland, Scott
Barber, Jack R.
Kantarjian, Hagop M.
BLOOD, 2009, 114 (22) : 809 - 810

← 1 2 3 4 5 →